+

WO1997033622B1 - Delivery of nucleic acids by porphyrins - Google Patents

Delivery of nucleic acids by porphyrins

Info

Publication number
WO1997033622B1
WO1997033622B1 PCT/US1997/004000 US9704000W WO9733622B1 WO 1997033622 B1 WO1997033622 B1 WO 1997033622B1 US 9704000 W US9704000 W US 9704000W WO 9733622 B1 WO9733622 B1 WO 9733622B1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
poφhyrin
oligonucleotide
composition
macrocycle
Prior art date
Application number
PCT/US1997/004000
Other languages
French (fr)
Other versions
WO1997033622A2 (en
WO1997033622A3 (en
Filing date
Publication date
Priority claimed from US08/616,141 external-priority patent/US6620805B1/en
Application filed filed Critical
Priority to EP97915946A priority Critical patent/EP0894011A2/en
Priority to AU23244/97A priority patent/AU2324497A/en
Priority to US08/912,378 priority patent/US6610478B1/en
Publication of WO1997033622A2 publication Critical patent/WO1997033622A2/en
Publication of WO1997033622A3 publication Critical patent/WO1997033622A3/en
Publication of WO1997033622B1 publication Critical patent/WO1997033622B1/en
Priority to US09/627,562 priority patent/US6558954B1/en

Links

Abstract

Efficient methods and compositions are provided for the targeted delivery of effective concentrations of compounds, including nucleic acid molecules and oligonucleotides such as EGSs, ribozymes and antisense, proteins, peptides, carbohydrate, and synthetic organic and inorganic molecules, or combinations thereof, to cells, especially hepatocytes. In the preferred embodiment, the compound is a negatively charged oligonucleotide which binds in a stoichiometric ratio to a water soluble, positively charged macrocycle such as a porphyrin, which targets and protects the oligonucleotide. The porphyrin protects the compound to be delivered and delivers the compound preferentially to certain cells and tissue types. In another embodiment, the porphyrin has anti-human hepatitis virus activity, when administered alone, which is significantly enhanced when in combination with an antiviral compound, especially an oligonucleotide.

Claims

AMENDED CLAIMS[received by the International Bureau on 9 March 1998 (09.03.98); original claims 1, 7, 19 and 24 amended; remaining claims unchanged (3 pages)]
1. A method for delivering a compound having a net negative charge to cells comprising mixing the compound with a macrocycle having a net positive charge in an amount effective to enhance delivery of the compound to cells binding the macrocycle, wherein the compound and the macrocycle are ionically bound together; and delivering the compound-macrocycle composition to the cells.
2. The method of claim 1 wherein the compound is selected from the group consisting of proteins, peptides, oligonucleotides, biologically active synthetic organic molecules, polysaccharides, and diagnostic reagents, wherein the compound has a net negative charge at physiological pH.
3. The method of claim 2 wherein the compound is an oligonucleotide.
4. The method of claim 3 wherein the oligonucleotide is selected from the group consisting of antisense nucleic acid molecules, ribozymes, external guide sequences for RNase P, aptamers, triplex molecules, genes, viral vectors, plasmids, and protein encoding sequences.
5. The method of claim 1 wherein the macrocycle is a porphyrin.
6. The method of claim 1 wherein the porphyrin is selected from the group consisting of natural porphyrins, natural phthalocyanins, synthetic porphyrins, synthetic phthalocyanins, and conjugates thereof.
7. The method of claim 1 wherein the compound is an oligonucleotide and the macrocycle is a poφhyrin further comprising mixing the poφhyrin and oligonucleotide in a ratio resulting in all of the oligonucleotide binding to the poφhyrin.
8. The method of claim 7 wherein the poφhyrin has antiviral activity.
9. The method of claim 8 wherein the poφhyrin has anti-hepatitis B activity.
42
10. The method of claim 9 wherein the poφhyrin is tetra meso (n- methyl 4-pyridyl) poφhine (TMP) or meso tetra (trimethyl anilinium) poφhine (TMA).
11. The method of claim 1 wherein the compound has anti-viral activity.
12. The method of claim 11 wherein the compound is an oligonucleotide targeted to viral nucleic acid.
13. The method of claim 12 wherein the viral nucleic acid is hepatitis viral nucleic acid.
14. A method for inhibiting hepatitis B infection of cells comprising administering to the cells an effective amount of a poφhyrin to inhibit replication of hepatitis B in the cells.
15. The method of claim 14 wherein the poφhyrin is selected from the group consisting of natural poφhyrins, natural phthalocyanins, synthetic poφhyrins, synthetic phthalocyanins, and conjugates thereof.
16. The method of claim 15 wherein the poφhyrin is a synthetic poφhyrin.
17. The method of claim 16 wherein the poφhyrin is tetra meso (n- methyl 4-pyridyl) poφhine (TMP) or meso tetra (trimethyl anilinium) poφhine (TMA).
18. The method of claim 14 wherein the poφhyrin is administered to a patient in need of treatment thereof.
19. A composition for delivering a compound having a net negative charge to cells comprising the compound ionically bound to a macrocycle having a net positive charge selected from the group consisting of natural poφhyrins, natural phthalocyanins, synthetic poφhyrins, synthetic phthalocyanins, and conjugates thereof, in an amount effective to enhance delivery of the compound to cells preferentially binding the macrocycle.
20. The composition of claim 19 wherein the compound is selected from the group consisting of proteins, peptides, oligonucleotides, biologically
43 active synthetic organic molecules, polysaccharides, and diagnostic reagents, wherein the compound has a net negative charge at physiological pH.
21. The composition of claim 20 wherein the compound is an oligonucleotide.
22. The composition of claim 21 wherein the oligonucleotide is selected from the group consisting of antisense nucleic acid molecules, ribozymes, external guide sequences for RNase P, aptamers, triplex molecules, genes, viral vectors, plasmids, and protein encoding sequences.
23. The composition of claim 19 wherein the macrocycle is a poφhyrin selected from the group consisting of natural poφhyrins, natural phthalocyanins, synthetic poφhyrins, synthetic phthalocyanins, and conjugates thereof.
24. The composition of claim 19 wherein the compound is an oligonucleotide and the macrocycle is a poφhyrin further comprising mixing the poφhyrin and oligonucleotide in a ratio resulting in all of the oligonucleotide binding to the poφhyrin.
25. The composition of claim 23 wherein the poφhyrin has antiviral activity.
26. The composition of claim 25 wherein the poφhyrin has anti- hepatitis B activity.
27. The composition of claim 26 wherein the poφhyrin is tetra meso (n-methyl 4-pyridyl) poφhine (TMP) or meso tetra (trimethyl anilinium) poφhine (TMA).
28. The composition of claim 26 wherein the poφhyrin is bound to oligonucleotide to be delivered.
29. The composition of claim 28 wherein the oligonucleotide is an external guide sequence for RNase P.
30. The composition of claim 19 wherein the compound is a protein or a peptide comprising L-amino acids or D-amino acids with a net negative charge.
44
PCT/US1997/004000 1996-03-14 1997-03-14 Delivery of nucleic acids by porphyrins WO1997033622A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP97915946A EP0894011A2 (en) 1996-03-14 1997-03-14 Delivery of nucleic acids by porphyrins
AU23244/97A AU2324497A (en) 1996-03-14 1997-03-14 Delivery of nucleic acids by porphyrins
US08/912,378 US6610478B1 (en) 1996-08-16 1997-08-15 Phenotypic conversion of cells mediated by external guide sequences
US09/627,562 US6558954B1 (en) 1996-08-16 2000-07-28 Phenotypic conversion of cells mediated by external guide sequences

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/616,141 US6620805B1 (en) 1996-03-14 1996-03-14 Delivery of nucleic acids by porphyrins
US08/616,141 1996-03-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/912,378 Continuation-In-Part US6610478B1 (en) 1996-08-16 1997-08-15 Phenotypic conversion of cells mediated by external guide sequences

Publications (3)

Publication Number Publication Date
WO1997033622A2 WO1997033622A2 (en) 1997-09-18
WO1997033622A3 WO1997033622A3 (en) 1998-02-26
WO1997033622B1 true WO1997033622B1 (en) 1998-04-16

Family

ID=24468218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/004000 WO1997033622A2 (en) 1996-03-14 1997-03-14 Delivery of nucleic acids by porphyrins

Country Status (4)

Country Link
US (1) US6620805B1 (en)
EP (1) EP0894011A2 (en)
AU (1) AU2324497A (en)
WO (1) WO1997033622A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
WO1998006837A1 (en) * 1996-08-16 1998-02-19 Yale University Phenotypic conversion of drug-resistant bacteria to drug-sensitivity
US6610478B1 (en) 1996-08-16 2003-08-26 Yale University Phenotypic conversion of cells mediated by external guide sequences
WO1998006440A2 (en) * 1996-08-16 1998-02-19 Innovir Laboratories, Inc. Phenotypic conversion of cells mediated by external guide sequences
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20020155999A1 (en) * 1998-04-30 2002-10-24 Han In Suk Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
BRPI0215088B1 (en) * 2001-12-20 2015-12-22 Sasol Tech Pty Ltd trimerization catalyst system and process for olefin oligomerization
US20050048641A1 (en) * 2002-11-26 2005-03-03 Medtronic, Inc. System and method for delivering polynucleotides to the central nervous system
JP2006512927A (en) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ,インコーポレイテッド 5 'CPG nucleic acids and methods of use thereof
GB2397067B (en) * 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
US7109173B1 (en) 2004-03-16 2006-09-19 Wilbert Gamble Transport of nucleotides, oligonucleotides and polynucleotides into the cytoplasm and nucleus of cells by peptides
GB2415372A (en) 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
US20070036740A1 (en) * 2004-10-06 2007-02-15 Reed Kenneth C Modulation of hair growth
EP1807514A1 (en) * 2004-10-22 2007-07-18 Benitec, Inc. Therapeutic rnai agents for treating psoriasis
EP1838853A2 (en) * 2005-01-06 2007-10-03 Benitec, Inc. Rnai agents for maintenance of stem cells
US20070128116A1 (en) * 2005-07-27 2007-06-07 Wang Zheng J Multifunctional core for molecular imaging and targeted delivery of macromolecules and drugs
GB0519169D0 (en) * 2005-09-21 2005-10-26 Leuven K U Res & Dev Novel anti-viral strategy
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc Modified sirna molecules and uses thereof
CA2710713C (en) 2007-12-27 2017-09-19 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
WO2009129319A2 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Silencing of csn5 gene expression using interfering rna
JP2013530187A (en) 2010-06-17 2013-07-25 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ Compositions and methods for treating inflammatory diseases.
WO2013075132A1 (en) 2011-11-17 2013-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Therapeutic rna switches compositions and methods of use
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
EP2817327A1 (en) 2012-02-21 2014-12-31 Institut National de la Sante et de la Recherche Medicale (INSERM) Tim receptors as virus entry cofactors
EP2817328A1 (en) 2012-02-21 2014-12-31 Institut National de la Santé et de la Recherche Médicale Tam receptors as virus entry cofactors
CN104736563A (en) 2012-07-27 2015-06-24 国家健康与医学研究院 Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2015019548A1 (en) * 2013-08-05 2015-02-12 パナソニック株式会社 Method for inhibiting dna degradation reaction, and dna degradation reaction inhibitor
JP2017536092A (en) 2014-10-02 2017-12-07 プロティバ バイオセラピューティクス インコーポレイテッド Compositions and methods for silencing gene expression of hepatitis B virus
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
CN108350455A (en) 2015-07-29 2018-07-31 阿布特斯生物制药公司 Composition for making hepatitis B virus silenced gene expression and method
WO2018038155A1 (en) * 2016-08-23 2018-03-01 国立大学法人東京大学 Micelle and use of same
US20200352913A1 (en) 2017-11-23 2020-11-12 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating dengue virus infection

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4104466A (en) 1974-03-13 1978-08-01 Eishun Tsuchida Polymeric metal complex and method of manufacturing the same
IL69720A (en) 1983-09-14 1987-08-31 Univ Ramot Anti-tumor pharmaceutical compositions comprising liposome-bound porphyrins
FR2567892B1 (en) 1984-07-19 1989-02-17 Centre Nat Rech Scient NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
GB2213684A (en) 1987-12-11 1989-08-16 Philips Electronic Associated Data demodulator baud clock phase locking
HUT54407A (en) 1987-12-15 1991-02-28 Commw Scient Ind Res Org Process for producing ribozimes
US5192788A (en) * 1988-05-23 1993-03-09 Georgia State University Foundation, Inc. Porphyrin antiviral compositions
FR2632187B1 (en) 1988-06-02 1990-09-14 Centre Nat Rech Scient METALLOPORPHYRIN DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION AND THEIR USE FOR THE PREPARATION OF HYBRID MOLECULES
US5225337A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
AU659482B2 (en) 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5607924A (en) 1992-01-21 1997-03-04 Pharmacyclics, Inc. DNA photocleavage using texaphyrins
FR2697254A1 (en) 1992-10-22 1994-04-29 Genset Sa New conjugate of oligo-nucleotide and cationic metallo-porphyrin - can cleave complementary nucleic acid selectively, useful as antitumour, antiviral, antibacterial and antiparasitic agent
US6012375A (en) 1993-07-06 2000-01-11 Eckstein; Donald B. Aircraft infrared guided defense missile system
EP0746614A1 (en) 1994-02-23 1996-12-11 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
US5691316A (en) 1994-06-01 1997-11-25 Hybridon, Inc. Cyclodextrin cellular delivery system for oligonucleotides
CA2191627A1 (en) 1994-06-02 1995-12-14 Zvi Malik Synergistic antibiotic compositions containing a perphyrin and an antibiotic

Similar Documents

Publication Publication Date Title
WO1997033622B1 (en) Delivery of nucleic acids by porphyrins
WO1997033622A3 (en) Delivery of nucleic acids by porphyrins
RU2623160C2 (en) Composition of delivery system based on conjugate for rna-interference polynucleotide delivery to liver cell and process for its preparation
CA2248538A1 (en) Targeted delivery of genes encoding interferon
WO1994023751A1 (en) Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells
EP1077070A3 (en) Oral drug delivery compositions
RU99118890A (en) WATER-SOLUBLE PHARMACEUTICAL COMPOSITION IN THE FORM OF ION COMPLEX AND ITS APPLICATION
CN107849567A (en) A kind of siRNA, the pharmaceutical composition containing the siRNA and conjugate and their application
CA2186118A1 (en) Compacted nucleic acids and their delivery to cells
WO1994013325A3 (en) Peptide linkers for improved oligonucleotide delivery
CA2536632A1 (en) Therapy-enhancing glucan
CA2102208A1 (en) Binding domains in notch and delta proteins
EP1198254A2 (en) Carrier-drug conjugate
CN108250267B (en) Polypeptide, polypeptide-siRNA induction co-assembly and application thereof
JPH05504566A (en) Wound treatment method using biologically active peptides
CA2352286A1 (en) Intracellular targeted delivery of compounds by 70 kd heat shock protein
DE69017180T2 (en) BIOLOGICALLY EFFECTIVE POLYMERS OF DRUG DERIVATIVES.
Ohmori et al. Importance of hydrophobic region in amphiphilic structures of α-helical peptides for their gene transfer-ability into cells
JPH06503714A (en) Long-term expression of polynucleotides introduced into cells
JPH07501793A (en) synthetic transfection vector
AU8748198A (en) Carcinostatic agents
AU720697B2 (en) Pharmaceutical composition which is useful for the transfection of nucleic acids, and uses thereof
AU784031B2 (en) Method for preparing polycation based bioconjugates suitable for transporting different kinds of active substances within the body
DE19935302A1 (en) Conjugates and processes for their preparation and their use for the transport of molecules across biological membranes
Ganguly et al. Pharmacokinetic analysis of polyamide nucleic-acid-cell penetrating peptide conjugates targeted against HIV-1 transactivation response element
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载